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IMPORTANCE Preliminary clinical trials have demonstrated that endobronchial coils compress
emphysematous lung tissue andmay improve lung function, exercise tolerance, and
symptoms in patients with emphysema and severe lung hyperinflation.
OBJECTIVE To determine the effectiveness and safety of endobronchial coil treatment.
DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted among 315 patients
with emphysema and severe air trapping recruited from 21 North American and 5 European
sites from December 2012 through November 2015.
INTERVENTIONS Participants were randomly assigned to continue usual care alone (guideline
based, including pulmonary rehabilitation and bronchodilators; n = 157) vs usual care plus
bilateral coil treatment (n = 158) involving 2 sequential procedures 4months apart in which
10 to 14 coils were bronchoscopically placed in a single lobe of each lung.
MAIN OUTCOMES ANDMEASURES The primary effectiveness outcomewas difference in
absolute change in 6-minute-walk distance between baseline and 12months (minimal
clinically important difference [MCID], 25 m). Secondary end points included the difference
between groups in 6-minute walk distance responder rate, absolute change in quality of life
using the St George’s Respiratory Questionnaire (MCID, 4) and change in forced expiratory
volume in the first second (FEV1; MCID, 10%). The primary safety analysis compared the
proportion of participants experiencing at least 1 of 7 prespecified major complications.
RESULTS Among 315 participants (mean age, 64 years; 52%women), 90%completed the
12-month follow-up.Median change in 6-minutewalk distance at 12monthswas 10.3mwith
coil treatment vs −7.6mwith usual care, with a between-group difference of 14.6m
(Hodges-Lehmann 97.5%CI, 0.4m to; 1-sided P = .02). Improvement of at least 25m
occurred in 40.0%of patients in the coil group vs 26.9%with usual care (odds ratio, 1.8 [97.5%
CI, 1.1 to]; unadjusted between-group difference, 11.8% [97.5%CI, 1.0% to]; 1-sided P = .01).
The between-group difference inmedian change in FEV1 was 7.0% (97.5%CI, 3.4% to; 1-sided
P < .001), and the between-group St George’s Respiratory Questionnaire score improved −8.9
points (97.5%CI, − to −6.3 points; 1-sided P < .001), each favoring the coil group.Major
complications (including pneumonia requiring hospitalization and other potentially
life-threatening or fatal events) occurred in 34.8%of coil participants vs 19.1% of usual care
(P = .002). Other serious adverse events including pneumonia (20% coil vs 4.5%usual care)
and pneumothorax (9.7% vs 0.6%, respectively) occurredmore frequently in the coil group.
CONCLUSIONS AND RELEVANCE Among patients with emphysema and severe hyperinflation
treated for 12 months, the use of endobronchial coils compared with usual care resulted in an
improvement in median exercise tolerance that was modest and of uncertain clinical
importance, with a higher likelihood of major complications. Further follow-up is needed to
assess long-term effects on health outcomes.
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P atientswith advancedemphysemaand severe lunghy-perinflation have few treatment options to relievedyspnea.1,2 Lung volume reduction surgery has been
shown to improve lung function, quality of life, and survival
in the subsetofpatientswithadvanced,heterogeneous,upper
lobe emphysema.3 However, relatively few patientswith em-
physema undergo lung
volume reduction sur-
gery because a minority
haveanupper lobe–domi-
nant heterogeneous pat-
tern of destruction and
postoperative complica-
tions can be severe.3-5 A less invasive bronchoscopic ap-
proach targeting patients with heterogeneous emphysema
involves segmental airway placement of unidirectional
valves resulting in lobar collapse and clinical improvement;
however, this approach is still investigational in North
America and restricted to patients without interlobar collat-
eral channels.6-8 Patients with advanced homogeneous
emphysema and/or presence of interlobar collateral ventila-
tion have very limited treatment options, essentially lung
transplantation or palliative support.
Endobronchial coils, 10- to 15-cm nitinol wires that re-
gain their preformed shape following deployment, are de-
signedtocompressemphysematous tissue, thus restoringelas-
ticproperties inadjacent lung tissueand improvingventilatory
mechanical function. Endobronchial coils havebeen tested in
patientswithbothheterogeneous andhomogeneous lungde-
structionwith orwithout incomplete interlobar fissures. Sev-
eral small clinical trials preliminarily reported that coils may
improve quality of life and exercise tolerance.7,9-14 The re-
cently published REVOLENS randomized clinical trial raised
questions with respect to effectiveness, including durability
of effect, optimal patient selection criteria, multiperformer
technical feasibility, and importance of short- and long-term
adverse events including pneumonia.14 The RENEW trial was
conducted to assess 1-year effectiveness and safety of endo-
bronchial coils on exercise tolerance, quality of life, and lung
function in patients with severe lung hyperinflation and ad-
vanced homogeneous or heterogeneous emphysema.
Methods
Study Oversight and Ethics
The institutional review boards at participating centers ap-
proved the study protocol (Supplement 1), which was over-
seen by an independent datamonitoring committee. Patients
were screened only after providing written informed con-
sent. This study was conducted in compliance with the prin-
ciples enunciated in the Declaration of Helsinki, the US clini-
cal investigative laws, and those laws appropriate for
participating centers in the European Union and Canada.
Study Participants
The trial enrolled patients aged 35 years or older with medi-
cally optimized emphysema (Figure 1). Participants were
former smokers who recently completed pulmonary reha-
bilitation and/or were participating in exercise mainte-
nance. Self-reported ethnicity and race were collected as
fixed categories per Clinical Data Interchange Standards
Consortium standards to appropriately adjust lung function
and to account for any potential differences by treat-
ment. Key inclusion criteria included postbronchodilator
forced expiratory volume in the first second (FEV1) of 45%
predicted or less, total lung capacity (TLC) of more than
100% predicted, and residual volume (RV) of at least 225%
predicted. The RV threshold was lowered to at least 175%
predicted following enrollment of 169 patients to ad-
dress the effectiveness and safety of endobronchial coils
in a broader patient population. Severe bronchitis/
bronchiectasis, comorbidities potentially affecting trial
completion, and significant reversible airflow obstruction
(postbronchodilator response >20%) excluded patients from
enrollment (eAppendix in Supplement 2).
Trial Design
This multicenter, randomized, assessor-blinded study com-
pared outcomes between treatment and control groups at 12
months. A radiology core laboratory reviewed scans for eli-
gibility, identified lobes for treatment, and classified the
type of emphysema (heterogeneous or homogeneous) (eFig-
ure 1 in Supplement 2) using a semiquantitative visual
assessment (Supplement 1). Upper lobes were preferentially
targeted in patients with homogeneously distributed dis-
ease based on physiologic modeling, preliminary surgical
experience, and a feasibility trial.12,15 Blinded block random-
ization (block size of 4) stratified by type of emphysema
occurred on a 1:1 basis between usual care (control group)
and usual care plus treatment with endobronchial coils
(PneumRx Inc) using a computerized, automated system
(Datatrak IWRS) directed by an independent contractor
(Pharm-Olam International).
Usual care was based on the Global Initiative for Chronic
Obstructive LungDisease (GOLD)2 guidelines,whereby treat-
ment was optimized in cooperation with the treating physi-
cian at the pretreatment visit. Each participant was encour-
agedtouse inhaled long-actingbronchodilatorswithorwithout
inhaled corticosteroids. Current influenza and pneumococ-
cus vaccinations were encouraged. Participants were re-
quired tocompleteapulmonary rehabilitationprogramwithin
6 months or be performing maintenance rehabilitation prior
to baseline testing. During theposttreatment period,medica-
tion adjustment for treatment of exacerbations was permit-
ted; however, changes to the medical regimen were other-
wisediscouragedandparticipantswereencouragedtocontinue
maintenance rehabilitation.
The treatment group, in addition to receiving usual care,
underwent implantation of 10 to 14 coils under fluoroscopic
guidance via bronchoscopy (eFigures 2 and 3 in Supplement
2). The choice of moderate sedation or general anesthesia
was determined by the investigator. The bronchoscopist
advanced the bronchoscope to the ostium of the target sub-
segmental airway and then advanced a catheter with a guide
wire into the bronchial segment of the treatment lobe to
FEV1 forced expiratory volume in the
first second
MCID minimal clinically important
difference
RV residual volume
TLC total lung capacity
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within a minimum of 3 cm of the pleural surface. The
selected coil length (100, 125, or 150 mm) was based on sub-
segmental airway length. Two sequential single-lobe treat-
ments of contralateral upper or lower lobes were performed
4 months apart (based on a conservative estimate of the
recovery time needed after a bronchoscopy for this severely
affected patient population) (Supplement 1).
Effectiveness Outcomes
All end points compared baseline data vs results at 12months
after first treatment. Participants were not blinded, although
walk and spirometry measurements were obtained using a
blinded assessor.
The primary effectiveness variable was the difference in
absolute change in 6-minute walk distance between baseline
and 12-month visit. Secondary end points included 6-minute
walk distance response, defined as a 25-m minimal clinically
important difference (MCID)16 in 6-minute walk distance;
mean percent change in FEV1 (MCID, 10%)17; and mean abso-
lute difference in St George’s Respiratory Questionnaire score
(range, 0-100, with higher scores indicating worse quality of
life). Six-minute walk testing, spirometry, and physiologic
testing were performed using established standards, with
participants carrying their oxygen at the prescribed flow rate
when necessary.18-21
Other exploratory effectiveness end points included
StGeorge’sRespiratoryQuestionnaire response,definedusing
a 4-point or greater score reduction as the MCID22; mean ab-
solutedifference inRV (MCID,0.35L)23measuredbybodyple-
thysmography; and mean absolute difference in RV/TLC.
Safety Outcome Assessment
The primary safety analysis reports the proportion of partici-
pants in thecoil andusual caregroupswhoexperiencedat least
1major complicationwithin 12months after baseline (eTable 1
inSupplement2).Allmajor complicationswereadjudicatedby
an independentclinicaleventscommittee inanunblindedfash-
ion to facilitate imaging review (eAppendix in Supplement 2).
Some participants experienced a focal lung tissue re-
sponse to coil treatment, identified on chest imaging and
Figure 1. Participant Flow in the RENEWRandomized Clinical Trial
685 Patients assessed for eligibility
370 Excluded
288 Did not meet inclusion criteria
168 Residual volume ≤225% of predicted
52 Disease condition or habit potentially 
interfering with study completion 
or outcomes
37 Diffusion capacity <20% of predicted
31 Change in forced expiratory volume
in the first second >20%
postbronchodilator response
24 Screening in process at enrollment close
58 Other reasons
158 Randomized to receive intervention therapy
155 Received intervention as randomized
3 Did not receive intervention
2 Withdrawn by investigator (eligible
for lung transplant)
1 Withdrew consent
141 Completed study through 12 mo
14 Did not complete study
10 Died
3 Withdrew consent
1 Eligible for lung transplant
315 Randomized
23 Missing efficacy end-point dataa
21 Missing 6-minute walk distance
21 Missing forced expiratory volume 
in the first second
22 Missing residual volume
20 Missing St George’s Respiratory 
Questionnaire score
158 Included in primary analysis
157 Randomized to receive control therapy
157 Received control as randomized
143 Completed study through 12 mo
14 Did not complete study
8 Died
2 Lost to follow-up
2 Had suspicious lung nodule
1 Severe chronic obstructive lung 
disease exacerbation
1 Withdrew consent
18 Missing efficacy end-point dataa
17 Missing 6-minute walk distance
17 Missing forced expiratory volume 
in the first second
17 Missing residual volume
18 Missing St George’s Respiratory 
Questionnaire score
157 Included in primary analysis
a Most patients with missing values
were included in all categories of
missing data.
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characterized during the course of this trial as coil-
associated opacity (eFigure 4 in Supplement 2). The RENEW
data monitoring committee adjudicated the investigator-
reported pneumonia adverse events and determined that
some of these events were misclassified and represented
coil-associated opacity.
Statistical Analysis
Based on previous studies, a sample size of 315 was selected
to provide greater than 95% power to detect a treatment dif-
ference in effectiveness, assuming 5% lost to follow-up and
treatment difference in change in 6-minute walk distance of
59 m (SD, 80 m) (the difference from baseline observed in
early feasibility trials) and in FEV1 of 0.05 L (SD, 0.10 L)
using a 1-sided t test at α = .025.6,24 Comparisons of the coil
group vs usual care in primary and secondary effectiveness
end points were tested using analysis of covariance (or non-
parametric rank analysis of covariance in the presence of
significant skewness) and logistic regression (for 6-minute
walk distance responder end point) controlling for the
covariates of corresponding baseline value, analysis center,
and emphysema status in an intention-to-treat (ITT) analy-
sis. Missing values were imputed 50 times using the Markov
chain Monte Carlo method of multiple imputation. Mean
between-treatment differences adjusted for covariates and,
for data that were significantly skewed, Hodges-Lehmann
median between-treatment differences adjusted for base-
line were reported with associated 97.5% confidence inter-
vals. The proportion of responders, odds ratios (ORs), and
97.5% CIs adjusted for covariates are reported for responder
end points. This study was designed as a pivotal study to
support regulatory product registration by testing the supe-
riority in effectiveness of the coil group over usual care
against the null hypothesis of equality or inferiority. There-
fore, all effectiveness analyses were 1-sided tests of superi-
ority at the α = .025 significance level comparing endobron-
chial coil treatment vs usual care. The Hochberg step-up
procedure was used to control the study-wise α for multiple
comparisons in secondary end points.25-28
Other effectiveness end points tested for statistical sig-
nificance included St George’s Respiratory Questionnaire
response analysis and mean absolute differences in RV and
RV/TLC and were not adjusted for multiple comparisons.
Post hoc analyses compared effectiveness between the coil
group and usual care separately by prespecified subgroups
for type of emphysema and baseline RV measurement using
the same methods as the primary and secondary effective-
ness analyses.
Between-group comparisons at baseline were based on
analysis of variance with a factor for investigational site,
stratified Cochran-Mantel-Haenszel test, or Fisher exact
test. Between-treatment comparison of proportions of par-
ticipants experiencing at least 1 major complication were
analyzed using a 2-sided Fisher exact test. All analyses were
conducted using SAS version 9.3 (SAS Institute Inc). For
detailed information about study methods, see the eAppen-
dix in Supplement 2 and the statistical analysis plan in
Supplement 3.
Results
Participants
Study enrollment began in December 2012, and the final
participant completed 12-month follow-up in November
2015. Six hundred eighty-five patients were screened at 34
sites; 315 patients were randomized to receive either endo-
bronchial coil treatment (n = 158) or usual care (control;
n = 157) at 21 North American and 5 European sites. Twelve-
month follow-up was completed by 90.2% of participants
(Figure 1). Three participants randomized to coil treatment
withdrew before the intervention. Baseline characteristics
were similar between groups (Table 1). This population was
notable for the severity of airflow obstruction and hyperin-
flation, the high prevalence of comorbidities, and the pre-
dominance of homogeneous emphysematous destruction
on chest computed tomography. Seventy-six percent of coil
vs 71% of usual care participants had “very severe” spiro-
metric disease based on the GOLD 4 guidelines. Extreme
hyperinflation was present, with a mean RV of 246% (SD,
39%) predicted in the coil group vs 245% (SD, 39%) pre-
dicted in usual care participants. The coil group had a
median of 2.0 (interquartile range [IQR], 1.0-4.0) nonpul-
monary major comorbidities vs 2.0 (IQR, 1.0-3.0) in the
usual care group (eTable 3 and eFigure 5 in Supplement 2);
43% vs 41% received long-term oxygen and 31% vs 27% had
been hospitalized in the year prior to enrollment in the coil
and usual care groups, respectively. Emphysema distribu-
tion on computed tomography was similar between groups
(77% with homogeneous and 23% with heterogeneous pat-
terns) (eFigure 1 in Supplement 2).
Procedures
Bilateral treatment was completed in 144 of 158 participants
assigned to coil treatment; 11 participants completedonlyuni-
lateral treatment due to death (n = 3) or clinical worsening
(n = 8).Among the treatments, 84.2%were inupper lobes and
15.8%were in lower lobes, with a median insertion of 10 and
12 to 13 coils, respectively (eTable 4 in Supplement 2). Proce-
dure durationwas 42minutes (SD, 16minutes)with amedian
hospital stay of 1 night (range, 0-15 nights).
Primary and Secondary 6-MinuteWalk Distance
Effectiveness End Points (ITT Population)
The median prespecified primary effectiveness end point of
change in 6-minute walk distance at 12 months was 10.3 m
(IQR, −33.0 to 45.0m) in coil-treated patients vs −7.6m (IQR,
−40.0 to 26.0 m) for usual care, with a median between-
groupdifference of 14.6m (Hodges-Lehmann97.5%CI, 0.4m
to ; 1-sided P = .02) (Table 2, Figure 2, and eTable 5A in
Supplement 2). The secondary effectiveness end point of
6-minutewalkdistance response rate revealed40.0%vs26.9%
favoring the coil group (OR, 1.8 [97.5% CI, 1.1 to ]; unad-
justed between-groupdifference, 11.8% [97.5%CI, 1.0% to];
1-sidedP = .01)Asmall subsetof 12participants in thecoilgroup
and 8 participants in the usual care group reported a 12-
month decline of greater than 100m (4 times the MCID).
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Table 1. Baseline Demographics and Disease Characteristicsa
Characteristics
Coil Treatment
(n = 158)
Usual Care
(n = 157)
Age, y 63.4 (8.05) 64.3 (7.76)
Female, No. (%) 86 (54.4) 79 (50.3)
Body mass indexb 24.9 (4.6) 24.5 (4.9)
Hispanic/Latino ethnicity, No. (%) 1 (0.6) 2 (1.3)
Race, No. (%)
Black or African American 6 (3.8) 4 (2.5)
White 151 (95.6) 152 (96.8)
Asian/other 1 (0.6) 1 (0.6)
GOLD stage 4, No. (%) 120 (75.9) 112 (71.3)
BODE score33c 5.96 (1.26) 6.03 (1.32)
Score of 7-10, No. (%) 51 (32.3) 52 (33.1)
Smoking history, pack-yearsd 50.7 (27.9) [n=157] 50.3 (23.5)
No. of nonrespiratory comorbiditiese 2.6 (2.0) 2.3 (1.8)
Median (IQR) 2.0 (1.0-4.0) 2.0 (1.0-3.0)
≥4 Baseline total nonrespiratory comorbidities,
No. (%)
45 (28.5) 39 (24.8)
Receiving continuous oxygen, No. (%) 68 (43.0) 64 (40.8)
Flow rate, L/min 2.5 (0.9) 2.3 (0.9)
Hospital visits, all causes, 0-12 mo prior to baseline,
No. (%)
49 (31.0) 43 (27.4)
Baseline inhaler category, No. (%)
Long-acting β agonist and/or long-acting muscarinic
antagonist plus inhaled corticosteroid
136 (86.1) 141 (89.8)
Long-acting β agonist and/or long-acting muscarinic
antagonist
15 (9.5) 13 (8.3)
Short-acting β agonist and/or short-acting muscarinic
antagonist alone
2 (1.3) 2 (1.3)
None 5 (3.2) 1 (0.6)
6-Minute walk distance, m 312.0 (79.1) 302.7 (79.3)
Median (IQR) 318.3 (251.5-361.0) 300.0 (244.0-356.6)
Type of emphysema, No. (%)
Heterogeneous 36 (22.8) 36 (22.9)
Homogeneous 122 (77.2) 121 (77.1)
FVC, L 2.47 (0.69) 2.46 (0.75)
FVC, % predicted 67.8 (14.3) 67.4 (15.0)
FEV1, L 0.71 (0.20) 0.72 (0.21)
FEV1, % predicted 25.7 (6.3) 26.3 (6.7)
FEV1/FVC, % 28.8 (6.8) 29.9 (6.8)
RV, L 5.28 (1.06) 5.33 (1.15)
RV, % predicted 245.9 (39.1) 244.5 (38.7)
TLC, L 7.87 (1.35) 7.92 (1.56)
TLC, % predicted 139.2 (15.6) 138.8 (16.1)
RV/TLC, % 67.1 (6.7) 67.3 (6.3)
DLCO, mL/min/mm Hg 8.12 (2.86) 8.15 (2.80)
DLCO, % predicted 34.1 (10.5) 34.5 (10.7)
St George’s Respiratory Questionnaire total scoref 60.1 (12.8) 57.4 (14.8)
mMRC Dyspnea Scale score, No. (%)
0/1 0 0
2 54 (34.2) 56 (35.7)
3 69 (43.7) 70 (44.6)
4 35 (22.2) 31 (19.7)
PaCO2, mm Hg 41.6 (5.6) 41.5 (5.3)
PaO2, mm Hg 68.0 (10.5) 69.2 (10.9)
Abbreviations: BODE, bodymass
index, airflow obstruction, dyspnea,
and exercise; DLCO, single-breath
diffusion capacity for carbon
monoxide; GOLD, Global Initiative for
Chronic Obstructive Lung Disease;
FEV, forced expiratory volume;
FEV1, forced expiratory volume in the
first second; FVC, forced vital
capacity; mMRC, Modified Medical
Research Council; RV, residual
volume; TLC, total lung capacity.
a Data are expressed as mean (SD)
unless otherwise indicated.
bCalculated as weight in kilograms
divided by height in meters
squared.
c Scores range from0 to 10, with
higher scores indicating worse
prognosis.
dOne coil group participant had a
history of smoking but hadmissing
smoking pack-year data.
e See eTable 3 in Supplement 2 for the
list of 15 nonrespiratory
comorbidities included in this
calculation.
f Scores range from0 to 100, with
higher scores indicating worse
quality of life.
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Other Secondary Effectiveness End Points (ITT Population)
Themeanbetween-groupdifference in absolute change in the
St George’s Respiratory Questionnaire total score was −8.9
points (97.5%CI, − to−6.3points; 1-sidedP < .001), predomi-
nantly achieved through improvement in the coil group. The
change in FEV1was 3.8% (IQR, −6.3% to 16.1%) in coil-treated
patients vs −2.5% (IQR, −8.9% to 4.4%) for usual care, with a
between-group difference estimate of 7.0% (Hodges-
Lehmann 97.5% CI, 3.4% to ; 1-sided P < .001) (Table 2,
Figure 2, and eTable 5B in Supplement 2).
Exploratory Effectiveness End Points (ITT Population)
The St George’s Respiratory Questionnaire response analysis
demonstrated significantly more participants withmeaning-
ful improvement in thecoil group (61.2%)vsusual care (27.7%);
for an unadjusted between-group difference of 31.6% (97.5%
CI, 20.5% to ; P < .001). Resting lung hyperinflation de-
creased in the coil group relative tousual care, representedby
between-group differences for RV of −0.31 L (97.5% CI, − to
−0.11 L; 1-sided P = .001) and for RV/TLC of −3.5% (97.5% CI,
− to −2.1%; 1-sided P < .001) (Table 2 and Figure 2). Descrip-
tive results of primary, secondary, and exploratory outcome
end points at interim time points are presented in eTable 6 in
Supplement 2.
Prespecified subgroup analyses were performed to as-
sess response stratified by degree of air trapping (RV ≥225%
vs <225% predicted) and by heterogeneous vs homogeneous
emphysemadistribution.TheRV≥225%groupand thehetero-
geneous emphysema group each had greater magnitudes of
treatment response in all primary and secondary effective-
ness end points compared with respective groups with RV of
less than 225% and homogeneous destruction, although the
study was not powered to test differences between sub-
groups.
Post Hoc Analyses (ITT Population)
Participants were stratified into 4 subgroups based on the
prespecified characteristics associated with lung hyperinfla-
Table 2. Effectiveness End Points for the Intention-to-Treat Populationa
End Point
Coil Treatment
(n = 158)
Usual Care
(n = 157) Between-GroupDifference for Coil
Treatment vs Usual
Care (97.5% CI)b P ValuecAt 12 mo
Within-Group Change
or Rateb At 12 mo
Within-Group Change
or Rateb
Primary end point
Change in 6-minute
walk distance,
median (IQR), md
319.7 (242.9 to 387.7) 10.3 (−33.0 to 45.0) 300.0 (233.2 to 350.0) −7.6 (−40.0 to 26.0) 14.6 (0.4 to) .02e
Secondary end points
6-minute walk distance
response rate, No. (%)
[95% CI]f
NA 63 (40.0)
[31.0 to 49.0]
NA 42 (26.9)
[18.9 to 35.0]
11.8 (1.0 to)g
OR: 1.8 (1.1 to)h
.01i
Change in FEV1,
median (IQR), %d
0.71 (0.58 to 0.88) 3.8 (−6.3 to 16.1) 0.68 (0.54 to 0.82) −2.5 (−8.9 to 4.4) 7.0 (3.4 to) <.001e
Change in St George’s
Respiratory
Questionnaire score,
mean (95% CI)j
51.9 (49.5 to 54.4) −8.1 (−10.2 to −6.0) 58.4 (55.9 to 60.9) 0.8 (−1.2 to 2.9) −8.9 (− to −6.3) <.001
Other end points
St George’s Respiratory
Questionnaire response
rate, No. (%) [95% CI]f
NA 97 (61.2)
[50.9 to 71.4]
NA 43 (27.7)
[18.6 to 36.8]
31.6 (20.5 to)g
OR: 4.1 (2.4 to)h
<.001i
Change in RV, mean
(95% CI), Lj
4.95 (4.75 to 5.14) −0.41 (0.57 to −0.25) 5.28 (5.07 to 5.49) −0.10 (−0.26 to 0.06) −0.31 (− to −0.11) .001
Change in RV/TLC,
mean (95% CI), %j
63.6 (62.4 to 64.8) −4.0 (−5.1 to −2.9) 67.3 (66.2 to 68.4) −0.5 (−1.6 to 0.6) −3.5 (− to −2.1) <.001
Abbreviations: FEV1, forced expiratory volume in the first second;
IQR, interquartile range; NA, not applicable; OR, odds ratio; RV, residual volume;
TLC, total lung capacity.
a The full intention-to-treat analysis set comprised all patients who were
randomized, with multiple imputation for missing values using theMarkov
Chain Monte Carlo method.
bResponse rates are adjusted for emphysema status and analysis center, and
corresponding baseline values from logistic regression are presented asNo. (%)
of patients and odds ratios between treatment groups. The frequency of
responderswas estimated frommultiple imputation results. For 6-minutewalk
distance, response rates are not adjusted for analysis center because of
incompletemodel convergence (eAppendix in Supplement 2).
Between-treatment differences in response rates are not adjusted for covariates.
c By analysis of covariance with factors of treatment, emphysema status,
analysis center, and corresponding baseline value, unless otherwise specified.
dMedian between-treatment differences adjusted for baseline using the
Hodges-Lehmann estimator. The nonparametric median between-treatment
difference is not the simple between-treatment difference in medians.
e By nonparametric rank analysis of covariance with factors of treatment,
emphysema status, analysis center, and corresponding baseline value.
The Shapiro-Wilk test indicated nonnormality of residuals (P < .001).
f Response in 6-minute walk distance was defined as an increase of at least 25
meters. Response in St George’s Respiratory Questionnaire score was defined
as a decrease of at least 4 points. The response rate represents the proportion
of patients achieving theseminimal clinically important differences.
g Unadjusted between-treatment difference in response rate.
h Adjusted OR.
i By logistic regression with factors of treatment, emphysema status, analysis
center, and corresponding baseline value. For 6-minute walk distance
response, analysis center was not included as a factor because of incomplete
model convergence (eAppendix in Supplement 2).
j Mean within-group change and between-treatment difference adjusted for
covariates from analysis of covariance.
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tion and emphysema distribution (Figure 3 and eTable 7 in
Supplement 2). Participants with both favorable attributes
(RV ≥225% predicted and heterogeneous distribution)
exhibited superior treatment responses (median 6-minute
walk distance, +29.1 m, FEV1 change +12.3%, and mean
St George’s Respiratory Questionnaire change, −10.1-point
difference in the coil group relative to usual care), while
those with less air trapping (RV <225% predicted) and
homogeneous disease exhibited between-treatment dif-
ferences of a median −16.7 m for 6-minute walk distance,
a median FEV1 change of 3.5%, and a mean St George’s
Respiratory Questionnaire change of−3.3 points. The sub-
group with homogeneous disease but greater air trapping
(RV ≥225% predicted) had a favorable treatment response in
all end points (median 6-minute walk distance, +20.7 m;
median FEV1 change, +8.3%; and mean St George’s Respira-
tory Questionnaire change, −10.0-point difference in the
coil group relative to usual care). The group expressing
heterogeneous disease with RV of less than 225% predicted
was too small for data to be interpreted but demonstrated a
mixed response. The RV threshold used, albeit prespecified,
was arbitrarily chosen, and a post hoc sensitivity analysis
Figure 2. Distribution of Effectiveness End Points for the Intention-to-Treat Analysis for Key OutcomeMeasures
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For all measures, the response rates were higher in the endobronchial coil group
based on reportedminimal clinically important differences (MCIDs).16,17,19,23
In contrast, the proportion of participants declining anMCID equivalent was
numerically greater for all measures in the usual care group. Note the small
number of very significant 6-minute walk distance decliners, particularly
in the coil group, that lowered themean response. All improver and decliner
rates were calculated with logistic regression with data from the full
intention-to-treat analysis set, with multiple imputation. For each histogram,
the bin interval was set at half of the MCID for that measure. In each bin, the
data are equal to or greater than the lower limit and less than the upper limit of
the bin. The bin widths for each histogram are for residual volume, 175mL;
forced expiratory volume in the first second (FEV1), 5%; 6-minute walk
distance, 12.5 m; and St George’s Respiratory Questionnaire, 2 points.
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(eTable 8 in Supplement 2) indicated that 200% predicted
may be a more sensitive response threshold.
The presence of comorbidities reduced the 12-month
6-minute walk distance outcome despite lung function
improvements. Compared with usual care, coil-treated par-
ticipantswith4ormore comorbidities (eTable9 inSupplement
2) had a 1.1-m relative decline in 6-minute walk distance
despite significant reduction in RV, in contrast to partici-
pants with 3 or fewer comorbidities, who had a relative
21.0-m improvement in 6-minute walk distance. Partici-
pants who exhibited cardiac-related comorbidity also dem-
onstrated a decline in 6-minute walk distance despite
improvements in lung function (eTable 10 in Supplement 2).
The RV <225% subgroup had the greatest prevalence of car-
diac disease and averaged more comorbidities than the sub-
group with greater severity of air trapping (RV ≥225%)
(eTable 11 in Supplement 2).
Safety End Points
There was no difference in deaths in the coil group (n = 10;
6.5%) vs the usual care group (n = 8; 5.1%) at 1 year (eTable 12
in Supplement 2). Total major complications occurred more
frequently in the coil group (n = 54; 34.8%) vs the usual care
group (n = 30; 19.1%; P = .002) (Table 3). This difference was
largely due to increased lower respiratory tract infections
(18.7% vs 4.5%; P < .001). There were 2 cases of hemoptysis
requiring intervention in the coil group.
There were 2 direct procedure-associated deaths; one
patient died during the initial coil procedure because of pul-
monary hemorrhage and respiratory failure leading to car-
Figure 3. Intention-to-Treat Analysis Response Rates for 4 EffectivenessMeasures in Subgroups Stratified
by EmphysemaDistribution and Degree of Air Trapping
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diac arrest, and another patient died of respiratory failure 6
days following the second coil procedure. Overall, serious
adverse events were similar between the 2 study groups
except with respect to pneumonia (coil group, n = 31 [20%]
vs usual care, n = 7 [4.5%]; P < .001) and pneumothorax
(coil group, n = 15 [9.7%] vs usual care, n = 1 [0.6%];
P < .001). Serious adverse events related to chronic obstruc-
tive pulmonary disease exacerbations tended to be more
frequent with coil treatment (n = 43; 27.7%) vs usual care
(n = 32; 20.4%; P = .15) but returned to the level of the usual
care group in the 9- to 12-month window (eTables 13 and 14
in Supplement 2).
Post Hoc Safety Analysis
Reported pneumonia events adjudicated by the data moni-
toring committee were determined to be noninfectious coil-
associated opacity in 14 of 40 adjudicable cases (35%)
(eTable 15 in Supplement 2). Coil participants with adjudi-
cated coil-associated opacity exhibited superior 12-month
effectiveness outcomes compared with patients without
coil-associated opacities or pneumonia; the median
6-minute walk distance response rate was 47.8% (95% CI,
20.1%-75.6%) vs 38.9% (95% CI, 27.6%-50.2%) and the
median FEV1 change was 10.8% (IQR, 3.5%-22.7%) vs
2.2% (IQR, −7.8% to 14.5%), respectively (eTable 16A in
Supplement 2). This contrasts with usual care participants
with pneumonia (n=13), who had worsening of all measures,
specifically a 7.8% 6-minute walk distance response rate,
with a median 6-minute walk distance decline of −25 m
(IQR, −66 to −0.6 m) and a median FEV1 change of −2.9%
(IQR, −11.5% to −1.6%) (eTable 16B in Supplement 2).
Discussion
In a multicenter trial, bilateral endobronchial coil treatment
in patients with severe lung hyperinflation and homoge-
neous or heterogeneous emphysema resulted in durable but
modest increases in6-minutewalkdistanceofuncertain clini-
cal importance, alongwith improved expiratory flow rate av-
eraging less thana clinically important difference, reducedair
trapping, and overall clinically important improvements in
quality of life. These improvements were associated with a
higher rate of pneumothorax, pneumonia, hemoptysis, and
chronic obstructive pulmonary disease exacerbations imme-
diately following the coil procedure and for severalmonths af-
ter coil implantation.
This study addresses a group of patients with advanced
predominantly homogenous emphysema who have few
treatment options. More than 75% of participants had a
homogeneous emphysema distribution that would exclude
them from consideration for surgical lung reduction and
from investigational endobronchial valve treatment
options.3,6,8,29 The improvement in lung function associ-
ated with quality-of-life improvement greater than 2 times
the established MCID at 1-year follow-up was consistent
Table 3. Major Complications and Important Serious Adverse Events Through 12Months in the Safety Population
No. (%) of Patientsa
Difference, % (95% CI)b P Valuec
Coil Treatment
(n = 155)
Usual Care
(n = 157)
Major complications
Any 54 (34.8) 30 (19.1) 15.7 (5.9 to 25.2) .002
Death 10 (6.5) 8 (5.1) 1.4 (−4.1 to 7.0) .64
Pneumothorax requiring extended chest tube
drainage >7 d
1 (0.6) 1 (0.6) 0.0 (−2.9 to 3.0) >.99
Hemoptysis requiring intervention 2 (1.3) 0 1.3 (−1.3 to 4.6) .25
COPD exacerbation requiring extended
hospitalization >7 d
18 (11.6) 13 (8.3) 3.3 (−3.4 to 10.2) .35
Lower respiratory tract infection, including
pneumonia, requiring intravenous antibiotics and/or
corticosteroids
29 (18.7) 7 (4.5) 14.3 (7.3 to 21.5) <.001
Respiratory failure requiring mechanical ventilation 6 (3.9) 6 (3.8) 0.0 (−4.7 to 4.8) >.99
Unanticipated bronchoscopy 0 0 NA
Other important serious adverse eventsd
Pneumoniae 31 (20.0) 7 (4.5) 15.5 (8.4 to 22.9) <.001
COPD exacerbation 43 (27.7) 32 (20.4) 7.4 (−2.1 to 16.7) .15
Hemoptysis 4 (2.6) 0 2.6 (−0.3 to 6.4)
Pneumothoraxf 15 (9.7)f 1 (0.6) 9.0 (4.3 to 14.7) <.001
Abbreviations: COPD, chronic obstructive pulmonary disease; NA, not
applicable.
a Patients were counted once at most for an event type.
bConfidence intervals calculated using the Newcombemethod.
c Difference in proportions compared using the Fisher exact test.
d The standard definition of serious adverse events includes events that are
life-threatening or result in death; require patient hospitalization or
prolongation of existing hospitalization; result in persistent or significant
disability/incapacity; or require intervention to prevent permanent
impairment or damage.
e This category combines infectious pneumonia and a localized, noninfectious
tissue response identified during the study and adjudicated by the data
monitoring committee to be a coil-associated opacity.
f Three additional pneumothorax events were reported but did not meet
serious adverse event criteria; thus, the total pneumothorax rate in the
treatment group was 11.6%.
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with reports from several smaller observational and ran-
domized studies.7,9-14 On the other hand, the difference in
6-minute walk distance of 14.6 m, while statistically signifi-
cant, was modest and less than the established MCID of
25 m. Furthermore, the lower confidence limit suggests the
responder difference between the 2 groups could be as low
as 1%. Our results compare with the 21-m 6-minute walk
distance improvement reported in the recent REVOLENS
randomized trial at the primary 6-month end point and con-
trast with greater responses observed in previous observa-
tional studies.24 In this trial, the 6-minute walk distance
response was skewed such that a significantly greater pro-
portion of clinically important responses in the coil group
relative to usual care was balanced by a small proportion of
severe declines in both the coil and usual care groups that
lowered the mean and median response differences
(Figure 2). The variable improvement in walk distance was
in part related to this study’s less restrictive inclusion crite-
ria; participants with less air trapping (RV <220% predicted)
were excluded from REVOLENS. The baseline walk dis-
tance, degree of hyperinflation, prevalence of prior hospi-
talization, and long-term oxygen use in this trial reflect
greater impairment than in those enrolled in prior surgical
and endobronchial volume reduction trials.3,6,8 One third of
this study’s participants would qualify for lung transplanta-
tion based on their BODE (body mass index, airflow
obstruction, dyspnea, and exercise) scores of 7 or higher.30
Furthermore, the inclusion of participants with multiple
comorbidities in this study’s cohort (eTable 3 and eFigure 5
in Supplement 2) and in REVOLENS likely attenuated the
6-minute walk distance response in both studies despite
improvements in lung function.
Althoughadverseevents includingpneumothoraxandhe-
moptysisweremorecommon in thecoil group, theeventsgen-
erally occurred in the periprocedural and postprocedural pe-
riods and events returned toward baseline in the months
following the secondprocedure, as has beendescribed inpre-
vious series.31 The 15% excess incidence of pneumonia in the
coil group vs usual care was nearly identical to that reported
in the REVOLENS trial.14 This study has expanded the under-
standing of these pneumonia-classified events by identifying
noninfectious coil-associated opacities that represent more
than one-third of events. These coil-associated opacities ap-
pear to represent coil-induced inflammatory or lung struc-
tural changes induced by stress forces from the coils on lung
parenchyma.
Treated participants reporting a pneumonia or coil-
associatedopacityeventhadbetteroutcomesat 12monthsthan
participantsnotexperiencing theseevents, in contrast tousual
care participants with pneumonia, who did very poorly, sug-
gestinga causal andmechanisticdifferencebetween the study
groups (eTable 16 in Supplement 2). Theplanned follow-upof
the RENEW cohort for 5 years will better elucidate the long-
term response and safety profile of treatment.
Wehave identifiedprespecifiedandmechanisticallyplau-
sible subgroups defined by degree of air trapping and disease
distribution that associate with greater treatment response
(Figure 3 and eTable 7 in Supplement 2). The variation in re-
sponsewithin these subgroups, given the exploratory nature
of this analysis, must be interpreted with caution but offers
preliminaryevidencetosupport futurevalidationof thesemea-
sures to enhance patient selection.
There are limitations in the interpretation of this
study’s results. The difficulty in implementing a sham con-
trol group prevented effective blinding of participants
and may have influenced subjective outcomes such as the
St George’s Respiratory Questionnaire. On the other hand,
theStGeorge’sRespiratoryQuestionnaire,whichwas themost
responsiveof this study’seffectivenessmeasures, trackedwith
more objective physiologic measures in the subgroup analy-
sis (Figure 3).Another limitationwas theuseof6-minutewalk
distance as the primary outcome measure. While 6-minute
walk distance can integrate the functional effects of complex
physiologic changes in lung mechanics such as reductions in
hyperinflation and air trapping, which may not always be re-
flected in more conventional expiratory flow measures, the
variance in the measure and ceiling effect can limit the re-
sponsiveness of the tool. Inclusion of a practice walk at all
evaluation time points or greater vigilance tomaintaining re-
habilitation following randomizationmighthave increased the
responsiveness of 6-minute walk distance and lessened the
baseline decline across study groups.32 Despite these limita-
tions, however, the broadness of this study’s inclusion crite-
ria, the large number of enrolled patients, the longer duration
of follow-up, and the inclusionofmultiple centers andcoil im-
planters provide insights regarding the potential clinical util-
ity of this therapy.
Conclusions
Among patients with emphysema and severe hyperinflation
treated for 12 months, the use of an endobronchial coil com-
pared with usual care resulted in an improvement in median
exercise tolerance that was modest and of uncertain clinical
importance, with a higher likelihood ofmajor complications.
Further follow-up is needed to assess long-term effects on
health outcomes.
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